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Abstract
Pulmonary arterial hypertension (PAH) is characterised by an increase in mean pulmonary arterial pressure which
almost invariably leads to right heart failure and premature death. More than 70% of familial PAH and 20%
of idiopathic PAH patients carry heterozygous mutations in the bone morphogenetic protein (BMP) type 2
receptor (BMPR2). However, the incomplete penetrance of BMPR2 mutations suggests that other genetic and
environmental factors contribute to the disease. In the current study, we investigate the contribution of autophagy
in the degradation of BMPR2 in pulmonary vascular cells. We demonstrate that endogenous BMPR2 is degraded
through the lysosome in primary human pulmonary artery endothelial (PAECs) and smooth muscle cells (PASMCs):
two cell types that play a key role in the pathology of the disease. By means of an elegant HaloTag system,
we show that a block in lysosomal degradation leads to increased levels of BMPR2 at the plasma membrane. In
addition, pharmacological or genetic manipulations of autophagy allow us to conclude that autophagy activation
contributes to BMPR2 degradation. It has to be further investigated whether the role of autophagy in the
degradation of BMPR2 is direct or through the modulation of the endocytic pathway. Interestingly, using an
iPSC-derived endothelial cell model, our findings indicate that BMPR2 heterozygosity alone is sufficient to cause
an increased autophagic flux. Besides BMPR2 heterozygosity, pro-inflammatory cytokines also contribute to an
augmented autophagy in lung vascular cells. Furthermore, we demonstrate an increase in microtubule-associated
protein 1 light chain 3 beta (MAP1LC3B) levels in lung sections from PAH induced in rats. Accordingly, pulmonary
microvascular endothelial cells (MVECs) from end-stage idiopathic PAH patients present an elevated autophagic
flux. Our findings support a model in which an increased autophagic flux in PAH patients contributes to a greater
decrease in BMPR2 levels. Altogether, this study sheds light on the basic mechanisms of BMPR2 degradation and
highlights a crucial role for autophagy in PAH.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Pulmonary arterial hypertension (PAH) is characterised
by an increase in mean pulmonary arterial pressure
(greater than 25 mmHg at rest), pulmonary capillary
wedge pressure (15 mmHg), and pulmonary vascular
resistance (greater than 3 Wood units) [1]. The disease
affects the pulmonary vasculature, which is obstructed
due to adverse vascular remodelling leading to ven-
tricular dysfunction. PAH is a rare condition with an
incidence of 2–7.6 cases per million adults per year [2].
Despite efforts to develop treatments leading to some
improvement in symptoms and outcomes, patients still
die prematurely of right heart failure [3,4].
The classification of PAH comprises non-hereditary
or idiopathic PAH (iPAH) and hereditary PAH, which
is mostly related to heterozygous germline mutations in
BMPR2 [5–8]. BMPR2 encodes for the bone morpho-
genetic protein (BMP) type 2 receptor, which belongs
to the transforming growth factor β (TGF-β) family. It
is a transmembrane serine/threonine kinase receptor,
which upon BMP binding mediates the activation of
intracellular Smad downstream effectors. Interestingly,
20% of iPAH patients also carry heterozygous mutations
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that compromise BMPR2 function [9]. Among PAH
patients, those with BMPR2 mutations develop a more
severe disease with worse survival [10].
Despite the above, the incomplete penetrance of
BMPR2 mutations (20–30%) suggests that other genetic
and environmental factors such as hypoxia, inflamma-
tion [11–15], alterations in oestrogen metabolism
[16,17], or infections [18] contribute to the disease.
Previously, autophagy imbalance has been associ-
ated with PAH [19]. Autophagy is a highly regulated
catabolic process that involves sequestration and lyso-
somal degradation of cytosolic components such as
dysfunctional organelles and misfolded proteins. Stress
conditions including hypoxia [20], reactive oxygen
species [21], inflammation [22] and DNA damage can
trigger autophagy. Microtubule-associated protein 1
light chain 3 beta-II (MAP1LC3B-II) is an autophagy
marker and a lipidated form of MAP1LC3B-I. It is
associated with autophagosomal membranes and is fun-
damental for the formation of the autophagosome [23].
Lee et al have shown an increase in MAP1LC3B-II
protein levels in lung tissue from iPAH patients com-
pared with controls [24]. However, an increase in
MAP1LC3B-II is not a measure of autophagic flux per
se, since it can also indicate an inhibition of autophago-
some clearance [23]. Therefore, it remained unclear
whether the increase in MAP1LC3B-II levels in iPAH
is due to autophagy activation rather than an impair-
ment in autophagy termination. Long et al have also
shown a relationship between autophagy and PAH
pathogenesis [25]. Rats suffering from the disease and
treated with the lysosomal inhibitor chloroquine, which
also inhibits autophagic degradation, were shown to
increase BMPR2 levels [25]. Interestingly, chloroquine
treatment was found to prevent the development of PAH
as well as its progression [25,26].
To date, the role of autophagy in PAH remains incon-
clusive, as well as its role in BMPR2 degradation. In
this study, we demonstrate that BMPR2 is degraded
through the lysosomal pathway in an autophagy-related
fashion in primary human pulmonary artery endothelial
cells (PAECs). Our data show, for the first time, that
BMPR2 heterozygosity causes an increase in autophagy
contributing to the reduction in BMPR2 levels. Like-
wise, we demonstrate that pro-inflammatory cytokines,
which are typically elevated in PAH, are sufficient to
trigger autophagy in PAECs. Finally, our results sug-
gest an increase in autophagy in lung sections from
PAH-induced rats based on MAP1LC3B upregulation.
Importantly, by means of bafilomycin A1 (BafA1) treat-
ment, we confirmed an augmented autophagic flux in
pulmonary microvascular endothelial cells (MVECs)
isolated from iPAH patients.
Materials and methods
Antibodies and reagents
The following anti-human antibodies were used:
mouse anti-BMPR2 (612292/clone 18; 1:500) from
BD Biosciences (Vianen, The Netherlands), mouse
anti-MAP1LC3B (0231-100/clone 5F10; 1:1000)
from Nanotools (Teningen, Germany), and mouse
anti-sequestosome 1 (SQSTM1) (sc-28359/clone D3;
1:1000) from Santa Cruz (Heidelberg, Germany). Rabbit
anti-autophagy related 7 (ATG7; 8558/clone D12B11;
1:1000) and rabbit anti-α/β-tubulin (2148; 1:5000)
were from Cell Signaling Technology (Leiden, The
Netherlands); mouse anti-actin (A5441/clone AC-15;
1:1000) was from Sigma-Aldrich (Steinheim, Germany)
and mouse anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH; MAB374/clone 6C5; 1:10 000)
was from Millipore (Amsterdam-Zuidoost, The
Netherlands). Rabbit (W4011) and mouse (W4021)
horseradish peroxidase-conjugated secondary antibod-
ies were from Promega (Leiden, The Netherlands),
and donkey anti-mouse Alexa Fluor 488 secondary
antibody (A-21202) was from Thermo Fisher Scientific
(Landmeer, The Netherlands). Hydroxychloroquine
(HCQ; H0915), BafA1 (B1793), pp242 (P0037), and
cycloheximide (CHX; 01810) were obtained from
Sigma-Aldrich. Rapamycin (rapa; S1039) was from
Selleck Chemicals (TE Huissen, The Netherlands).
Bortezomib (BTZ; SC-217785) was from Santa Cruz
and MG-132 (474790) was from Millipore. Tumor
necrosis factor alpha (TNF-α; 300-01A) and interleukin
1 beta (IL-1β; 200-01B) were obtained from PeproTech
(London, UK). Autophinib (auto; 6324/10) was from
Tocris Bio-Techne (Abingdon, UK).
Cell culture
Human dermal microvascular endothelial cells
(HMEC-1; ATCC, CRL-3243) were cultured in
MCDB131 media (10372019; Thermo Fisher Scientific)
supplemented with 10% fetal bovine serum (FBS),
10 nM L-glutamine (25030-032; Invitrogen, Breda,
The Netherlands), 1 μg/ml hydroxycortisone (H0888;
Sigma), 10 ng/ml epidermal growth factor (EGF;
01-107; Millipore), and 1 ml of penicillin (30 mg/ml)–
streptomycin (48 mg/ml).
PAECs (CC-2530) were purchased from Lonza
(Basel, Switzerland) and were used between pas-
sages 4 and 8. Cells were maintained in Endothelial
Cell Basal Medium 2 (C-22211), supplemented with
ECGM-2 SupplementPack (C-39211) from PromoCell
(Heidelberg, Germany).
Human pulmonary artery smooth muscle cells
(PASMCs) were purchased from Lonza (CC-2581) and
were used between passages 4 and 8. Cells were cultured
in SmBM-2 Smooth Muscle Basal medium (CC-3181;
Lonza) supplemented with SmGM-2 Smooth Mus-
cle SingleQuot kit (CC-4149; Lonza). Wild-type and
BMPR2+/− iPSC-ECs (generated and differentiated as
previously described [27]) were maintained in Endothe-
lial Cell Growth Medium MV 2 (c-22221; PromoCell)
supplemented with 2% FBS, 1/100 Chemically-Defined
Lipid Concentrate, 50 μg/ml ascorbic acid, 15 μg/ml
transferrin, 7 μg/ml rh-insulin, 5 ng/ml FGF2, 20 ng/ml
rhVEGF-A165, 10 μM SB 431542, and 5 μM DAPT.
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Pulmonary MVECs were obtained from end-stage PAH
patients and healthy tissues of lobectomy donors (Table
1), as described before [28]. The tissue harvesting and
MVEC isolation were approved by the IRB of the
VU University Medical Center (VUmc, Amsterdam,
The Netherlands) and informed consent was given.
Pulmonary MVECs were cultured in complete ECM
medium supplemented with 1% pen/strep, 1% endothe-
lial cell growth supplement, and 5% FCS (ScienceCell,
Uden, The Netherlands). Cell lines were routinely
tested for mycoplasma contamination and used only if
negative.
Cell line generation
To generate an HMEC-1 line expressing Halo-BMPR2,
HMEC-1 cells were transduced with a lentiviral plasmid
with puromycin resistance carrying HaloTag-BMPR2
driven by an elongation factor1 (EF1)-α promoter.
Cells were maintained in MCDB131 media, as was
the parental cell line, and in the presence of 1.5 μg/ml
puromycin (p7255; Sigma-Aldrich).
siRNA transfections
PAECs were transfected with 10 nM of human
autophagy related 5 (ATG5; L-004374-00-0005), ATG7
(L-020112-00-0005) or BMPR2 (L-005309-00) RNAi
(Thermo Scientific) using Lipofectamine RNAiMAX
(13778075; Invitrogen). siRNA/Lipofectamine
RNAiMAX complexes were allowed to form for
20 min at room temperature before being added to the
cells. The media were changed 24 h after transfection.
After 48 h, cells were treated and cell lysates were
obtained. Knockdown efficiency was confirmed by
immunoblotting or mRNA expression.
Cell imaging
HaloTag staining
HMEC-1-HaloTag-BMPR2 cells were treated overnight
with BafA1 (20 nM). Next, they were incubated in
MCDB131 media containing the non-permeable
HaloTag Alexa Fluor 488 ligand (G1001; Promega)
at a dilution of 1:10 × 103 for 15 min at 37∘C. Cells
were then washed three times with medium and images
were recorded on a Leica DMi1 microscope.
Cyto-ID staining
Wild-type and BMPR2+/− iPSC-ECs were incubated
in Endothelial Cell Growth Medium MV 2 (c-22221;
PromoCell) (supplemented as described previously
above) with Cyto-ID Autophagy Detection dye
(ENZ-51031-0050; Enzo Life Sciences, Brussels,
Belgium) at a dilution of 1:500 for 25 min at 37∘C.
Subsequently, cells were washed and images were
recorded using a Leica (Wetzlar, Germany) DMi8
microscope.
Immunofluorescence microscopy
Rat lung tissues were fixed and stained as previously
described [29]. In brief, paraffin sections were deparaf-
finised and rehydrated. Sections were boiled for 40 min
in Vector® Antigen Unmasking Solution (Vector) using
a pressure cooker. After blocking with 1% BSA in
0.1% PBS, sections were incubated overnight at 4∘C
with primary antibodies directed against MAP1LC3B
(1:50) and PECAM1 (AF3628; 1:1000) from R&D
(Wiesbaden-Nordenstadt, Germany). All sections were
mounted with ProLong® Gold antifade reagent (Invit-
rogen) containing DAPI to counterstain the nuclei.
Flow cytometry analysis
HMEC-1-HaloTag-BMPR2 cells were treated overnight
with pp242 (1 μM). Cells were then trypsinised
and incubated in MCDB131 media containing the
non-permeable HaloTag Alexa Fluor 488 ligand (G100;
Promega) at a dilution of 1:2000 for 15 min at 37∘C.
Subsequently, cells were washed twice with medium
and analysed by flow cytometry. All data were analysed
using FlowJo software (BD).
Western blot quantification
Films were scanned and saved as .tiff files at 300 dots
per inch (dpi). Single protein bands were quantified
using ImageJ software. The resulting peaks represent
the relative density of the respective lanes. Background
signals were subtracted from the final quantification by
drawing a baseline on the bottom of each peak. The
numbers obtained for the measured area under the peak
have arbitrary units and can only be compared within
each particular blot. The same procedure was followed
for the loading controls. The relative quantity of protein
with respect to the loading control was then calculated.
Array scan imaging
PAECs were plated in a 96-well plate and treated with
BafA1 (20 nM), TNF-α (30 ng/ml), and IL-1β (10 ng/ml)
overnight. Cells were then washed twice with PBS and
fixed with cold methanol for 10 min at −20∘C. Subse-
quently, cells were washed twice with PBS and incu-
bated for 1 h at room temperature with MAP1LC3B
or SQSTM1 antibody at a dilution of 1:50 in PBS
with 1% BSA. Cells were then washed with PBS con-
taining 1% BSA and incubated for 1 h with donkey
anti-mouse Alexa Fluor 488 secondary antibody at a
dilution of 1:250 in PBS with 1% BSA. Next, cells
were washed twice with PBS and stained with Hoechst
33342 (2 μM) (62249; Thermo Fisher Scientific) for
10 min at room temperature. Sixty images per well were
captured in both Hoechst and Alexa Fluor 488 chan-
nels on a Cellomics ArrayScan VTI (Thermo Scien-
tific) using a 20 × 0.45 NA lens. Images were analysed
using the Cellomics Spot Detector V4 Bioapplication
(Thermo Scientific). Autofocusing was carried out on
Hoechst-stained nuclei. Exposure times were fixed for
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Table 1. Characteristics of controls and iPAH patients
No mPAP (mm Hg) Treatment Sex Age (years) Surgery
1 NA NA F 47 Lob
Controls 2 NA NA M 89 Lob
3 NA NA M 69 Lob
Idiopathic PAH patients
1 43 PDE5-I, PGI2 F 42 Ltx
2 102 PDE5-I, ERA, PGI2 M 21 Ltx
3 47 PDE5-I, ERA F 64 Obd
4 89 PDE5-I, ERA, PGI2 F 22 Ltx
mPAP, mean pulmonary artery pressure; NA, not available; PDE5-I, phosphodiesterase type 5 inhibitor; PGI2, prostacyclin; ERA, endothelin receptor antagonist; Lob,
lobectomy; Obd, obduction; Ltx, lung transplantation.
each individual experiment. Each nucleus was identified
as a primary object in the Hoechst channel. MAP1LC3B
and SQSTM1 spots were detected within a 24-pixel
mask defined around the nucleus. The ‘spot total inten-
sity per object’ was reported and used to determine
changes in MAP1LC3B and SQSTM1.
RT-qPCR
Total RNA was isolated using a NucleoSpin RNA
kit (740955; Macherey Nagel, Duren, Germany)
according to the manufacturer’s protocol. RNA was
reverse-transcribed using a RevertAid RT Reverse Tran-
scription Kit (K1691; Thermo Fisher Scientific). The
generated cDNA was amplified with primer pairs for
the indicated gene, using the CFX Connect Real-Time
PCR Detection System (Bio-Rad). GAPDH was used as
the reference transcript. Quantification was performed
relative to the levels of GAPDH and normalised to
control conditions. The data analysis was performed
using the 2−ΔΔCt method. Primer sequences are listed in
the supplementary material, Table S1.
Statistical analysis
Unpaired two-sided Student’s t-tests were used to cal-
culate statistical differences. A P value of less than 0.05
was considered statistically significant.
Results
Inhibition of lysosomal degradation results
in increased BMPR2 levels in primary human
pulmonary artery endothelial cells
Although BMPR2 degradation has been studied before,
there is still discrepancy in the results as both protea-
somal degradation [30] and lysosomal [31] degradation
of BMPR2 have been reported in different cell types.
To investigate the mechanisms by which endogenous
BMPR2 is degraded in the context of PAH, PAECs
were treated with the lysosomal inhibitors BafA1 and
HCQ and with the proteasome inhibitors MG-132
and BTZ. BMPR2 levels significantly increased after
treatment with lysosomal inhibitors, while treatment
with proteasome inhibitors did not result in BMPR2
accumulation (Figure 1A). To validate the specificity
of the antibody, BMPR2 was knocked down using
siRNA and shRNA. As expected, there was a promi-
nent reduction in BMPR2 expression after knockdown
(supplementary material, Figure S1). To confirm that
the increase in BMPR2 protein levels was due to a
block in lysosomal degradation rather than an increase
in mRNA levels, RT-qPCR analysis of BMPR2 was
performed in PAECs after BafA1 treatment (supple-
mentary material, Figure S2). No significant differences
were observed, indicating that BMPR2 accumulation
occurs in response to inhibition of lysosomal degra-
dation. To establish whether lysosomal degradation of
BMPR2 is cell type-dependent, PASMCs and HMEC-1
(previously immortalised by others [32]) were also
treated with the different inhibitors (Figure 1B,C). As
expected, accumulation of BMPR2 was only detected
after treatment with BafA1 and HCQ (Figure 1B,C). To
elucidate whether the increase in BMPR2 occurs at the
plasma membrane, HMEC-1 stably expressing BMPR2
coupled to an N-terminal Halo tag (Halo-BMPR2)
(supplementary material, Figure S3A) were generated.
BMPR2 overexpression and increased BMP signalling
were verified by western blotting (supplementary mate-
rial, Figure S3B). The Halo tag allows for measurement
of the BMPR2 protein level at the cell surface, using a
non-cell-permeable Halo fluorescent ligand. By means
of fluorescence microscopy and this ligand, the amount
of Halo-BMPR2 was measured after BafA1 treatment.
The amount of Halo-BMPR2 strongly increased upon
BafA1 treatment when compared with untreated cells
(Figure 1D).
Taken together, these data indicate that endogenous
BMPR2 is degraded through the lysosomal pathway
and that inhibition of lysosomal degradation results in
BMPR2 accumulation at the plasma membrane.
Autophagy modulation affects BMPR2 lysosomal
degradation
Two major vesicular processes convening on the
lysosome are endocytosis and autophagy [33]. Impor-
tantly, chloroquine and HCQ have been found to exert
beneficial effects in experimental PAH, possibly by
modulating autophagy and lysosomal degradation [25].
To investigate the contribution of autophagy in the
pathogenesis of PAH, we explored whether autophagy
modulation affects BMPR2 lysosomal degradation
in endothelial cells. Human PAECs and HMEC-1
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 356–367
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
360 MC Gomez-Puerto et al
Figure 1. BMPR2 is degraded through the lysosomal pathway in human PAECs, PASMCs, and HMEC-1. (A–C) BMPR2 protein levels increased
after treatment with lysosomal inhibitors. Left panel: western blot analysis of BMPR2 protein levels after (A) PAECs, (B) PASMCs, and (C)
HMEC-1 were treated for 6 h with BafA1(20 nM), HCQ (20 μM), MG-132 (5 μM), and BTZ (10 nM). Tubulin or actin was used as a loading
control. Representative results of at least three independent experiments are shown. Right panels: quantification of BMPR2 levels normalised
to the loading control is presented as mean± SEM. *p < 0.05; **p < 0.005; ***p < 0.001. (D) Cell surface expression of BMPR2 after inhibition
of lysosomal degradation. HMEC-1-Halo-BMPR2 were treated with BafA1 (20 nM) for 16 h and stained with the non-permeable Halo Alexa
Fluor 488 ligand. Left panel: Fluorescence microscopy images of BMPR2 localisation are shown. Images are representative of at least three
independent experiments. Right panel: quantification of HMEC-1-Halo-BMPR2 mean fluorescence intensity is shown. Data are presented
as mean± SEM. ****p < 0.0001.
Halo-BMPR2 were treated with the autophagy inducers
rapa [34] and pp242 [35] and changes in BMPR2 protein
expression were detected by western blot (Figure 2A,B).
Autophagy activation resulted in a significant decrease
in BMPR2 protein levels, suggesting a relationship
between autophagy stimulation and BMPR2 degra-
dation (Figure 2A,B). Similar results were obtained
after starvation-induced autophagy (supplementary
material, Figure S4A). The amounts of BMPR2 protein
at the plasma membrane were analysed by quantifying
Halo-BMPR2 fluorescence intensity using flow cytom-
etry (Figure 2C). As expected, HMEC-1 Halo-BMPR2
treated with pp242 showed a decrease in mean fluores-
cence intensity, compared with the control. To further
confirm the role of autophagy in BMPR2 degradation,
ATG7, a critical component regulating the elongation
and closure of the phagophore membrane [36] was
knocked down in PAECs by means of siRNAs. mRNA
and protein levels of ATG7 were analysed, confirming
its depletion (Figure 2D). In addition, to confirm a
reduction in autophagy after ATG7 downregulation, the
levels of the autophagy marker MAP1LC3B-II were
measured by western blot (Figure 2D). Since ATG7
knockdown does not abrogate autophagy completely,
cells were treated with BafA1 to impair the remaining
autophagic flux after ATG7 depletion. Besides being an
inhibitor of V-type ATPase and certain P-type ATPases
preventing the acidification of the lysosome, BafA1 also
blocks the fusion of autophagosomes with lysosomes
[23,37]. Importantly, ATG7-knockdown cells showed
an increase in BMPR2 levels both in the presence
and in the absence of BafA1 (Figure 2E). As ATG7
has autophagy-independent roles [38], to further val-
idate our findings, ATG5 required for MAP1LC3B-I
lipidation was knocked down in PAECs (supplemen-
tary material, Figure S4C). Subsequently, cells were
treated with CHX to stop protein synthesis excluding de
novo BMPR2 protein production. Likewise, a block in
autophagy after ATG5 depletion resulted in increased
BMPR2 protein levels independently of CHX treatment
(supplementary material, Figure S4C). Taken together,
these findings show that autophagy modulation in
human PAECs affects BMPR2 lysosomal degradation.
BMPR2 heterozygosity and inflammation are
sufficient to cause an increase in autophagy
in endothelial cells
More than 70% of patients with hereditary PAH show
heterozygous mutations that compromise BMPR2
function. Additionally, patients with such mutations
present a more severe disease [10]. We therefore eval-
uated whether BMPR2 heterozygosity could result in
an increased autophagy contributing to the reduction
of BMPR2 levels. As a model, BMPR2+/−-induced
pluripotent stem cells (iPSCs) carrying a known causal
BMPR2 mutation (W9X) and an otherwise isogenic
wild-type iPSC line were differentiated towards ECs
and sorted using magnetic microbeads conjugated with
human PECAM1/CD31 and CDH5/CD144 antibodies
[27]. A reduction in BMPR2 expression in BMPR2+/−
iPSC-ECs, when compared with control iPSC-ECs, was
confirmed by western blotting analysis (Figure 3A).
Subsequently, autophagic turnover was studied by
analysing the levels of MAP1LC3B-II. The level of
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Figure 2. BMPR2 is degraded via lysosomes in an autophagy-related fashion. (A, B) Western blot analysis of BMPR2 protein levels after
autophagy activation. Left panel: (A) PAECs and (B) HMEC-1-Halo-BMPR2 were treated for 6 h with rapa (10 μM) and pp242 (1 μM). Tubulin
was used as a loading control. Representative results of at least three independent experiments are shown. Right panels: quantification
of BMPR2 levels normalised to tubulin is presented as mean± SEM. *p < 0.05; **p < 0.005. BMPR2 protein levels at the plasma membrane
decrease after autophagy activation. (C) Flow cytometry-based analysis of Halo-BMPR2 by means of the non-permeable Halo Alexa Fluor
488 ligand after HMEC-1-Halo-BMPR2 were treated with pp242 (1 μM) for 16 h. Left panel: flow cytometry plots. Right panel: quantification
of the fold Alexa Fluor 488 ligand mean fluorescence intensity upon pp242 (1 μM) treatment. The data are presented as fold increases relative
to untreated control. Data of four independent experiments are presented as mean± SEM. **p < 0.005. (D) ATG7 knockdown efficacy was
examined. Left panel: ATG7 mRNA expression was analysed by RT-qPCR. Data of three independent experiments performed in duplicates are
presented as mean± SEM. ***p < 0.001, normalised to GAPDH. The data are presented as fold increases relative to the control. Right panel:
western blot showing ATG7 and MAP1LC3B protein expression. GAPDH was used as a loading control. Representative results of at least
three independent experiments are shown. (E) Left panel: western blot showing BMPR2 protein levels after blocking autophagy. PAECs were
transfected with control or ATG7 siRNA followed by 6 h BafA1 treatment. Tubulin was used as a loading control. Representative results of at
least three independent experiments are shown. Right panel: quantification of BMPR2 levels normalised to the loading control is presented
as mean± SEM. *p < 0.05.
MAP1LC3B-II is not a measure of autophagic flux per
se, as it can also indicate an inhibition of autophagosome
clearance [23]. BMPR2+/− iPSC-ECs were therefore
treated with BafA1 to prevent lysosomal degrada-
tion and to block the fusion of autophagosomes with
lysosomes. Independently of the inter-experimental
differences in MAP1LC3B-II levels, MAP1LC3B-II
was upregulated in the presence of BafA1 in BMPR2+/−
iPSC-ECs, compared with control iPSC-ECs, indi-
cating an increase in autophagic flux (Figure 3B). To
validate our findings, autophagy changes were mea-
sured by fluorescence microscopy using Cyto-ID, a dye
selectively labelling autophagic vacuoles. BMPR2+/−
iPSC-ECs showed an increase in autophagic vacuoles,
compared with control iPSC-ECs (Figure 3C). Taken
together, these data indicate that BMPR2 heterozygosity
is sufficient to cause an increase in autophagy in ECs.
An incomplete penetrance of BMPR2 mutations
suggests that other genetic and environmental fac-
tors contribute to PAH. Since inflammation is a
hallmark of the disease [11,13], we further inves-
tigated whether inflammatory cytokines previously
found to be upregulated in PAH [11,14] would trigger
autophagy in PAECs. MAP1LC3B and SQSTM1, an
autophagy adaptor protein whose levels are used as
a reporter of autophagy activity [39,40] were anal-
ysed by fluorescence microscopy after PAECs were
treated with the pro-inflammatory cytokines TNF-α
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Figure 3. Legend on next page.
[39] or IL-1β [15] in the presence or absence of BafA1
(Figure 3D). Cells treated with pro-inflammatory
cytokines showed a marked increase in MAP1LC3B
and SQSTM1-positive puncta, indicating increased
formation of autophagosomes (Figure 3D). To further
validate our findings, MAP1LC3B-II and SQSTM1
levels were measured by western blotting analysis
(Figure 3E). As expected, there was an accumulation
in both MAP1LC3B-II and SQSTM1 protein levels
after TNF-α and IL-1β treatment in the presence of
BafA1, compared with cells treated with BafA1 alone
(Figure 3E). Our results demonstrate that inflammation
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increases autophagic flux in PAECs. TNF-α has been
shown to reduce BMPR2 transcription in PAECs and
PASMCs [11]. To investigate whether TNF-α-induced
autophagy contributes to a decrease in BMPR2, PAECs
and HMEC-1 were stimulated with TNF-α and BafA1,
which impairs autophagy completion by inhibiting
the fusion of the autophagosome with the lysosome
(Figure 3F). Moreover, PAECs were treated with
TNF-α in the presence of autophinib (auto), a novel
autophagy inhibitor targeting VPS34 [40] (Figure 3G).
As expected, TNF-α treatment resulted in reduced
BMPR2 levels. However, when cells were treated with
BafA1 (Figure 3F) or auto (Figure 3G) together with
TNF-α, the decrease in BMPR2 levels, when compared
with TNF-α alone, was less prominent.
Autophagy flux is increased in idiopathic pulmonary
arterial hypertension
To investigate whether autophagy is upregulated in
PAH, the levels of MAP1LC3B were determined by
immunofluorescence in lung samples from two PAH rat
models: monocrotaline (MCT) and SU5416/hypoxia
(SuHx) [41]. Reduced BMP signalling and BMPR2
levels have been shown in MCT and SuHx models
[41]. In control rats, MAP1LC3B was present at a low
level, while in PAH-induced rats, MAP1LC3B levels
increased prominently (Figure 4A), possibly indicating
an increase in autophagy. The representative control
image for the MCT rat model shows a green fluores-
cence signal different to the green signal in MCT-treated
rats. Therefore, in the supplementary material, Figure
S5, we show how this unspecific signal is also visible
in the red channel. The signal seems to correspond
to autofluorescent erythrocytes. This is probably due
to the improper perfusion of the vessels before fixing
the tissue. As mentioned before, an accumulation in
MAP1LC3B may indicate a block in downstream steps
of autophagy rather than an increase in the autophagic
flux [45]. To further elucidate whether autophagy is
upregulated in PAH, pulmonary MVECs obtained from
end-stage idiopathic PAH patients (iPAH) and healthy
tissues of lobectomy donors (control) (Table 1) were
used (Figure 4B). iPAH patients did not harbour muta-
tions in the BMPR2 gene. Remarkably, a reduction in the
upper band of BMPR2, which corresponds to the fully
glycosylated mature form of the receptor [42,46], was
observed in three out of four iPAH MVECs compared
with control MVECs (Figure 4B). N-Glycosylation of
BMPR2 has been shown to enhance its ability to bind
BMP2 ligand [42]. Interestingly, the N126 glycosylation
site has been found mutated in patients with hereditary
PAH [43].
Next, autophagic flux was analysed after control
and iPAH MVECs were treated with BafA1, result-
ing in an augmented BafA1-induced accumulation of
MAP1LC3B-II (Figure 4C). The reduction in the upper
band of BMPR2 in iPAH MVECs corresponds to an
increase in MAP1LC3B-II. We are presently unable to
explain the significance of this result. Taken together,
these data indicate an augmented autophagy flux as a
prominent characteristic of PAH.
Discussion
We have demonstrated that endogenous BMPR2 is
mainly degraded through the lysosome in PAECs and
PASMCs, two cell types that play a key role in the
pathology of the disease. Satow et al have shown that
BMPR2 is degraded via the proteasomal pathway in
HEK 293T cells when it is associated with Dullard
phosphatase [30]. In contrast, we have shown that in
lung vascular endothelial cells, treatment with pro-
teasome inhibitors resulted in a slight reduction of
BMPR2 levels. This could be explained by a known
induction of autophagy after treatment with proteasome
inhibitors [44,47,48]. An increase in MAP1LC3B-II
protein levels after BTZ and MG-132 treatment in
Figure 3. W9X mutation in BMPR2 and inflammation are sufficient to induce autophagy in endothelial cells. (A) Western blot showing
BMPR2 protein expression after BMPR2+/− iPSC-ECs and isogenic control iPSC-ECs were treated for 6 h with BafA1(20 nM). Tubulin was used
as a loading control. Representative results of three independent experiments are shown. (B) Left panel: western blot of three independent
experiments showing MAP1LC3B protein expression after BMPR2+/− iPSC-ECs and control iPSC-ECs were treated for 6 h with BafA1 (20 nM).
Tubulin was used as a loading control. Quantification of MAP1LC3B levels normalised to the loading control is presented as mean± SEM.
*p < 0.05. Right panel: western blot showing SQSTM1 protein expression after BMPR2+/− iPSC-ECs and control iPSC-ECs were treated
for 6 h with BafA1 (20 nM). Actin was used as a loading control. Representative results of three independent experiments are shown.
Quantification of SQSTM1 levels normalised to the loading control is presented as mean± SEM. (C) Autophagic vesicles were quantified
using Cyto-ID. Left panel: representative fluorescence microscopy images. Right panel: quantification of the Cyto-ID mean fluorescence
intensity. The data are presented as fold increases relative to Hoechst. Data of three independent experiments are shown as mean± SEM.
**p < 0.005. (D, E) PAECs were treated with TNF-α (30 ng/ml) and IL-1β (10 ng/ml) for 16 h or 24 h with and without BafA1 (20 nM). (D)
Cells were fixed and stained for MAP1LC3B and SQSTM1. MAP1LC3B and SQSTM1 were analysed by fluorescence microscopy (array scan).
Left panel: representative images showing MAP1LC3B staining in green. Array scan quantification based on ‘spot total intensity per object’.
Quantification of data from three independent experiments performed in duplicates is shown as mean± SEM. **p < 0.005. Right panel:
representative images showing SQSTM1 staining in red. Array scan quantification based on ‘spot total intensity per object’. Quantification
of data from three independent experiments performed in duplicates is shown as mean± SEM. ****p < 0.0001. (E) Left panel: cells were
lysed and MAP1LC3B and SQSTM1 levels were analysed by western blotting. Actin was used as a loading control. Representative results of
three independent experiments are shown. Right panel: quantification of MAP1LC3B and SQSTM1 levels normalised to the loading control
is presented as mean± SEM. **p < 0.005; ****p < 0.0001. (F, G) BMPR2 levels were analysed by western blotting after cells were stimulated
with TNF-α (30 ng/ml) and BafA1 (20 nM) or auto (0.1 μM), respectively.
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Figure 4. Increased autophagy is a hallmark of PAH. (A) Lung sections from MCT, SuHx, and control rats were immunostained for MAP1LC3B.
Representative pictures showing MAP1LC3B staining in green, DAPI-positive nuclei in blue, and platelet endothelial cell adhesion molecule
(PECAM-1) in white. (B) Western blot showing BMPR2 protein expression of MVECs from iPAH patients and controls. Tubulin was used as a
loading control. (C) Left panel: western blot showing MAP1LC3B and SQSTM1 protein expression. MVECs from iPAH patients and controls
were treated for 16 h with BafA1 (20 nM). Tubulin was used as a loading control. Right panel: quantification of MAP1LC3B and SQSTM1
levels normalised to tubulin is presented as mean± SEM. *p < 0.05.
PAECs further validates this hypothesis (supplemen-
tary material, Figure S6A). The discrepancy between
the studies could be due to the comparison between
endogenous and overexpressed BMPR2 degradation.
The different outcomes also suggest more than one
mechanism for BMPR2 degradation depending on the
cell type.
Treatment with pharmacological activators of
autophagy, as well as ATG7 and ATG5 depletion, con-
firms that in lung vascular endothelial cells, autophagy
modulation affects BMPR2 lysosomal degradation. It
is worth mentioning that the two lysosomal inhibitors
used, BafA1 and HCQ, are also known to block
autophagy by impairing autophagosome fusion with
lysosomes. The exact way in which autophagy con-
tributes to BMPR2 degradation still has to be elucidated
as it could be direct or through modulation of the
endocytic pathway.
Here, we have demonstrated for the first time that
BMPR2 heterozygosity is sufficient to cause an increase
in autophagy. The transcript for the W9X mutation
in the iPSC is degraded by nonsense-mediated decay;
therefore, the increased autophagy flux is not a response
to misfolded protein accumulation. However, we cannot
exclude that autophagy is triggered to clear dysfunc-
tional mitochondria present in BMPR2+/− iPSC-ECs
[27]. Furthermore, it would be interesting to under-
stand the role of BMPR2 signalling in the regulation
of autophagy and how corruption of the BMPR2
pathway contributes to its activation. As BMP9 and
BMP10 circulate in the blood and selectively bind
to BMPR2, we wondered whether the activation of
this pathway orchestrates a negative regulation of
autophagy [49,50]. Our findings show a decrease in
MAP1LC3B-II after PAECs were treated with BMP9
and BafA1, compared with BafA1 alone (supplemen-
tary material, Figure S7A). In this way, the binding of
BMP9 to BMPR2 results in a blockage of autophagy
that may inhibit BMPR2 degradation, promoting its
signalling.
Our data suggest that an increase in autophagy
is present in lung sections from experimental rat
models based on MAP1LC3B upregulation. In
addition, in the same way as Lee et al showed an
increase in MAP1LC3B-II protein levels in lung tis-
sue from iPAH patients [24], we demonstrated an
increase in MAP1LC3B-II in pulmonary MVECs
from iPAH patients. However, by looking at the
levels of MAP1LC3B-II after BafA1 treatment,
we do conclude that this is due to an increased
autophagic flux.
Both BMPR2+/− iPSC-ECs and MVECs from iPAH
patients show an increased autophagy flux. Never-
theless, while SQSTM1 levels were augmented in
BMPR2+/− iPSC-ECs when compared with control
iPSC-ECs, the expression of SQSTM1 in iPAH MVECs
diminished compared with control MVECs (data not
shown). Although autophagy induction often corre-
sponds to a decrease in SQSTM1 levels, SQSTM1
may be transcriptionally upregulated under certain
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conditions [23]. In addition, a transient increase in
the amount of SQSTM1 has been shown in some
situations where there is an increase in autophagic
flux [23]. Finally, SQSTM1 has been found to exert
autophagy-independent roles that might contribute to
the contradictory results observed [51].
Besides BMPR2 mutations, insults such as inflam-
mation, chronic hypoxia, and shear stress have been
found to be involved in the pathogenesis of PAH.
We demonstrated that the pro-inflammatory cytokines
TNF-α and IL-1β, previously found to be implicated
in PAH [15,39,52], trigger autophagy in PAECs. Hurst
et al reported that TNF-α reduces BMPR2 transcription
in PAECs [11]. In the present study, we showed that
TNF-α-induced autophagy also contributes to a decrease
in BMPR2 levels. One of the presumed mechanisms on
how inflammation induces autophagy might be through
ERK1/2 MAP kinase pathway activation [28,53]. In
addition, TNF-α has also been shown to upregulate the
expression of the autophagy genes LC3 and beclin 1
through Jun kinase signalling pathway activation and
AKT/PKB inhibition [22].
Both hereditary and idiopathic forms of PAH fre-
quently display reduced BMPR2 levels either due to
mutations in BMPR2 [10], inflammation [13] or infec-
tions [18]. Our findings support a model in which an
increased autophagic flux in PAH patients contributes
to a greater decrease in BMPR2 levels. It will be of
interest to identify adaptor proteins involved in BMPR2
degradation as well as specific ubiquitin ligases and
post-translational modifications which orchestrate this
process.
Although our study reveals the possibility of
inhibiting autophagy as a treatment for PAH, specific
autophagy inhibitors have to be discovered and char-
acterised. A remaining question is whether autophagy
is one of the initial causes of PAH or whether it is a
cellular response to counteract stress conditions that
could eventually contribute to the severity of the dis-
ease. Altogether, our study sheds light on the basic
mechanisms of BMPR2 degradation and highlights the
crucial role of autophagy in PAH.
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